Brief: Shanghai Fosun Pharma's Unit Gets Approval For Clinical Trial Of FXR0906 From NMPA China
15/07/2026 11:25
BRIEF-Shanghai Fosun Pharma's Unit Gets Approval For Clinical Trial Of FXR0906 From NMPA China July 15 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:
UNIT GOT APPROVAL FROM NMPA CHINA FOR CLINICAL TRIAL OF FXR0906 FOR TREATMENT OF HYPERTRIGLYCERIDEMIA
Further company coverage: 600196.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Fosun Pharmaceutical
See all newsSHH Margin Trading -- Fosun Pharma Margin Long Amount is 1,592 (x10000) yuan, Short Selling Volume is 5 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,031 (x10000) yuan, Short Selling Volume is 1 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,109 (x10000) yuan, Short Selling Volume is 10 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,131 (x10000) yuan, Short Selling Volume is 0.21 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 1,865 (x10000) yuan, Short Selling Volume is 0.15 (x10000) shares